Molbio Diagnostics IPO was a Mainboard Book Built public issue by Molbio Diagnostics Limited. The public issue comprised a fresh issue of equity shares aggregating to ₹200 crore along with an Offer for Sale (OFS) of 91,66,000 equity shares by existing shareholders. The equity shares were listed on both the BSE and NSE on August 17, 2026. The company had filed its Red Herring Prospectus with SEBI on August 7, 2026.
The IPO was priced in the range of ₹768 to ₹807 per equity share with a face value of ₹1 per share. The total issue size was approximately ₹939.70 crore, comprising a fresh issue of approximately ₹200 crore and an OFS of approximately ₹739.70 crore. The proceeds from the fresh issue were to be received by the company, while the OFS proceeds were to be received by the respective selling shareholders.
Molbio Diagnostics Limited is a point-of-care diagnostics company focused on developing, manufacturing and commercialising accurate, rapid and cost-effective diagnostic technologies for infectious and non-communicable diseases. Its flagship Truenat platform is a portable, battery-operated real-time PCR system designed to enable decentralised molecular testing, including in resource-limited healthcare settings.
The company’s Truenat platform supports molecular testing for a wide range of diseases, including tuberculosis, HIV, malaria, viral hepatitis, COVID-19, dengue, chikungunya, influenza, HPV and other diseases. The company states that Truenat is patented in more than 100 countries and has been deployed across more than 55 countries.
Molbio has developed an integrated diagnostics ecosystem covering molecular diagnostics, digital pathology, radiology and breast health screening through its businesses, subsidiaries and associated entities. The company has also expanded its global presence through exports and strategic partnerships with healthcare organisations and international public-health programmes.
The diagnostics industry is supported by increasing healthcare awareness, demand for early disease detection, decentralisation of testing, expansion of public healthcare programmes and growing adoption of molecular diagnostics. At the same time, investors should carefully evaluate government and institutional procurement dependence, regulatory requirements, technological changes, competition, customer concentration and valuation before making an investment decision.
IPO Details
| Information | Details |
| IPO Name | Molbio Diagnostics IPO |
| Company Name | Molbio Diagnostics Limited |
| IPO Type | Book Built Issue |
| IPO Category | Mainboard IPO |
| Face Value | ₹1 Per Equity Share |
| Price Band | ₹768 to ₹807 Per Share |
| Issue Size | Approx. ₹939.70 Crore |
| Fresh Issue | Approx. ₹200 Crore |
| Offer for Sale | 91,66,000 Equity Shares |
| IPO Open Date | 10 August 2026 |
| IPO Close Date | 12 August 2026 |
| Anchor Investor Bidding | 7 August 2026 |
| Basis of Allotment | 13 August 2026 |
| Refund Initiation | 14 August 2026 |
| Shares Credited to Demat Account | 14 August 2026 |
| Listing Date | 17 August 2026 |
| Listing Exchange | BSE & NSE |
| Lot Size | 18 Equity Shares |
| Registrar | KFin Technologies Limited |
| Book Running Lead Managers | Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited and Motilal Oswal Investment Advisors Limited |
The company proposed to use the fresh issue proceeds primarily for capital expenditure relating to its research and development facility and Centre of Excellence, purchase of plant, machinery and equipment for selected manufacturing units, and general corporate purposes.
Molbio Diagnostics IPO Dates
| IPO Event | Date |
| Anchor Investor Bidding | 7 August 2026 |
| IPO Opening Date | 10 August 2026 |
| IPO Closing Date | 12 August 2026 |
| Basis of Allotment | 13 August 2026 |
| Refund Initiation | 14 August 2026 |
| Shares Credited to Demat Account | 14 August 2026 |
| Listing Date | 17 August 2026 |
The Molbio Diagnostics IPO opened for subscription on August 10, 2026 and closed on August 12, 2026. The basis of allotment was finalised on August 13, followed by refunds and demat credit on August 14. The shares were listed on August 17, 2026.
Molbio Diagnostics IPO Reservation
| Investor Category | Reservation |
| Qualified Institutional Buyers (QIB) | 50% |
| Non-Institutional Investors (NII) | 15% |
| Retail Individual Investors (RII) | 35% |
The IPO allocation was divided between QIB, NII and retail investors according to the applicable Mainboard IPO allocation framework. The reported offer comprised 58,23,123 shares for the QIB category, 17,46,937 shares for NIIs and 40,76,186 shares for retail investors.
Molbio Diagnostics IPO Lot Size
| Application | Shares | Amount |
| Retail Minimum | 1 Lot (18 Shares) | ₹14,526 |
| Retail Maximum | 13 Lots (234 Shares) | ₹1,88,838 |
| S-HNI Minimum | 14 Lots (252 Shares) | ₹2,03,364 |
| S-HNI Maximum | 68 Lots (1,224 Shares) | ₹9,87,768 |
| B-HNI Minimum | 69 Lots (1,242 Shares) | ₹10,02,294 |
The application values shown above are calculated using the upper price band of ₹807 per equity share. The minimum retail application required 18 shares, resulting in an investment of ₹14,526 at the upper price band.
About Molbio Diagnostics Limited
Molbio Diagnostics Limited was incorporated in 2000 and operates in the point-of-care diagnostics segment. The company focuses on developing and commercialising molecular diagnostic technologies that can deliver rapid and accurate testing closer to the patient.
Its flagship Truenat platform was developed to decentralise molecular diagnostics by combining portable equipment, automated sample preparation and real-time PCR testing. The company says the platform can operate in diverse healthcare environments, including remote and resource-constrained locations.
Truenat consists of the Trueprep AUTO V2 sample preparation system and Truelab real-time quantitative micro-PCR analysers. The company states that the complete workflow from sample collection to result can be completed in approximately 60 minutes, depending on the test.
Molbio has expanded its portfolio beyond tuberculosis testing and offers assays for multiple infectious and non-infectious conditions. Its diagnostic platform is also supported by patents, regulatory approvals and collaborations in several international markets.
The company has also expanded into adjacent healthcare technologies through businesses such as digital pathology and radiology. Its official website identifies solutions including Truenat, iBreastExam, ProRad Atlas and OptraScan within its broader healthcare technology portfolio.
Business Operations
Molbio Diagnostics Limited operates across point-of-care molecular diagnostics and related healthcare technology solutions.
- Truenat Molecular Diagnostics – The company’s flagship Truenat platform provides portable real-time PCR testing for multiple diseases.
- TB Diagnostics – Truenat supports molecular detection of tuberculosis and rifampicin resistance and has received international recognition for its role in decentralised TB testing.
- Infectious Disease Testing – The platform supports testing for diseases including HIV, malaria, hepatitis, dengue, chikungunya, influenza, COVID-19 and other infections.
- Non-Communicable Disease Testing – Truenat also supports selected molecular tests for non-infectious conditions, including HLA-B27.
- Diagnostic Devices – The company’s ecosystem includes Trueprep AUTO V2 and Truelab PCR analysers used as part of the Truenat workflow.
- Digital Pathology – Molbio’s healthcare technology portfolio includes OptraScan through its associated business interests.
- Radiology Solutions – The company also has exposure to radiology technology through its broader healthcare solutions portfolio.
- Breast Health Screening – Molbio’s portfolio includes iBreastExam for breast health screening applications.
- Research and Development – Research and innovation remain central to the company’s business model, with Bigtec serving as an important R&D arm.
- International Operations – Molbio has expanded Truenat into international markets and stated that its products have reached more than 55 countries.
Industry Overview
The molecular diagnostics industry is benefiting from increasing demand for rapid and accurate disease detection. Traditional laboratory-based diagnostics can require centralised infrastructure, specialised personnel and transportation of samples. Point-of-care molecular diagnostic platforms can reduce these limitations by enabling testing closer to the patient.
The demand for decentralised diagnostics is particularly relevant in rural and resource-limited healthcare environments where access to advanced laboratories can be limited. Public health programmes for tuberculosis, infectious diseases and disease surveillance can further support demand for portable molecular testing.
Technological development is also increasing the range of diseases that can be tested using molecular platforms. Multiplex testing, automation, portable instruments and faster turnaround times can improve the efficiency of diagnostic services.
However, the diagnostics industry is subject to regulatory approvals, quality requirements and technological competition. Companies that depend significantly on government procurement, international aid programmes or large institutional customers may also face changes in tender volumes, procurement policies and healthcare spending.
Business Strategy
Molbio Diagnostics Limited focuses on expanding access to decentralised molecular diagnostics through continued product development, research and manufacturing investment.
The company is investing in a new research and development facility and Centre of Excellence, while also expanding manufacturing infrastructure at its Goa and Visakhapatnam facilities. The IPO proceeds were intended to support these investments.
Molbio also aims to expand the applications of its Truenat platform by developing additional assays and addressing a broader range of infectious and non-communicable diseases. Its portable and battery-operated architecture allows the platform to be deployed across hospitals, laboratories, primary healthcare facilities and remote healthcare locations.
The company is also focused on international expansion. Its Truenat platform has been exported to numerous countries and is used in public-health programmes and healthcare settings outside India.
Molbio Diagnostics IPO Financial Information
A company’s financial performance provides valuable information about its revenue growth, profitability, asset base and operating performance. Reviewing multiple financial years helps investors understand the consistency of the business and the underlying growth trajectory.
Molbio Diagnostics Financial Summary
| Particulars | FY2024 | FY2025 | FY2026 |
| Revenue from Operations | ₹836.56 Crore | ₹1,020.42 Crore | ₹1,445.69 Crore |
| Profit Before Tax | ₹109.67 Crore | ₹181.80 Crore | ₹215.66 Crore |
| Profit After Tax | ₹83.54 Crore | ₹138.58 Crore | ₹164.14 Crore |
| Total Assets | ₹1,221.06 Crore | ₹1,461.56 Crore | ₹2,148.42 Crore |
Molbio reported growth in revenue from operations from ₹836.56 crore in FY2024 to ₹1,020.42 crore in FY2025 and ₹1,445.69 crore in FY2026. PAT increased from ₹83.54 crore in FY2024 to ₹138.58 crore in FY2025 and ₹164.14 crore in FY2026.
The company has also reported increasing sales of Truenat devices and test kits. In FY2026, it sold 2,524 Truenat devices and approximately 1.76 crore test kits, compared with 2,180 devices and approximately 1.22 crore test kits in FY2025.
Revenue from the sale of test kits increased from ₹552.55 crore in FY2024 to ₹730.96 crore in FY2025 and ₹1,034.82 crore in FY2026, reflecting the growing contribution of recurring consumables to the business.
Molbio Diagnostics IPO Key Performance Indicators (KPIs)
Key Performance Indicators help investors assess profitability, capital efficiency, operating margins and valuation.
| KPI | Value |
| Return on Equity (ROE) | 15.23% |
| Return on Capital Employed (ROCE) | 20.98% |
| PAT Margin | 13.48% |
| Earnings Per Share (EPS) | ₹14.24 |
| Price to Earnings (P/E) | Approx. 56.67x |
The reported IPO-related valuation metrics indicate a P/E of approximately 56.67 times, while ROCE was reported at approximately 20.98%, RONW at approximately 15.23% and EPS at ₹14.24. Investors should compare these metrics with the company’s growth rate and listed diagnostic-sector peers before making an investment decision.
Objects of the Molbio Diagnostics IPO
The company intended to utilise the net proceeds from the fresh issue for the following purposes:
- Funding capital expenditure towards setting up infrastructure for a research and development facility, Centre of Excellence and connected office space.
- Funding capital expenditure towards the purchase of plant, machinery and other equipment for Goa Unit I, Goa Unit II and the Visakhapatnam Unit.
- General corporate purposes.
The reported allocation included approximately ₹105.54 crore towards the R&D facility, Centre of Excellence and connected office infrastructure and approximately ₹72.28 crore towards plant, machinery and equipment. The remaining amount was allocated for general corporate purposes.
The proceeds from the Offer for Sale were received by the respective selling shareholders and did not accrue to Molbio Diagnostics Limited.
Molbio Diagnostics IPO Listing Performance
The listing performance reflects the initial market response after the company’s shares began trading on the stock exchanges. Molbio Diagnostics shares were listed on both BSE and NSE on August 17, 2026.
| Particular | Value |
| Listing Exchange | BSE & NSE |
| Listing Date | 17 August 2026 |
| Issue Price | ₹807 Per Share |
| NSE Listing Price | ₹1,036.80 Per Share |
| Listing Gain | ₹229.80 Per Share |
| Listing Gain (%) | 28.47% |
| NSE Listing-Day Closing Price | ₹1,036.30 |
Molbio Diagnostics made a strong market debut, with the shares listing at approximately ₹1,036.80 on NSE against the issue price of ₹807, representing a gain of about 28.47%. The stock subsequently closed its first trading day around ₹1,036.30.
The listing performance reflects initial market sentiment and should not be considered a guarantee of future returns. Long-term performance will depend on revenue growth, profitability, product adoption, regulatory developments, international expansion and valuation.
Molbio Diagnostics IPO Subscription Status
The Molbio Diagnostics IPO received strong investor demand during its three-day bidding period. The final issue subscription reached approximately 70.26 times the shares available for subscription.
Molbio Diagnostics IPO Subscription
| Investor Category | Final Subscription |
| Qualified Institutional Buyers (QIB) | 186.39x |
| Non-Institutional Investors (NII) | 49.80x |
| Retail Individual Investors (RII) | 12.96x |
| Total Subscription | 70.26x |
The QIB category was subscribed approximately 186.39 times, while the NII category was subscribed 49.80 times and the retail category 12.96 times. Overall, the IPO received bids for approximately 57.32 crore shares against 81.58 lakh shares available in the issue.
Molbio Diagnostics IPO GMP
Grey Market Premium (GMP) is an unofficial and unregulated indicator of investor sentiment before an IPO listing. It is not part of the official IPO process and does not guarantee the listing price or future share price.
During the IPO period, market sources reported a positive GMP for Molbio Diagnostics. However, GMP figures can change quickly and should not be treated as an official company disclosure.
The actual NSE listing price of approximately ₹1,036.80 was substantially above the ₹807 issue price. Investors should focus on the company’s financial performance, business fundamentals, valuation and future growth prospects rather than relying solely on grey-market indications.
Molbio Diagnostics IPO Review
Molbio Diagnostics Limited operates in the growing molecular diagnostics sector and has developed a differentiated position through its Truenat point-of-care PCR platform. The company’s technology is designed to make molecular testing more accessible outside traditional centralised laboratories.
One of the company’s key strengths is its proprietary Truenat ecosystem. The platform combines portable hardware, sample preparation and disease-specific assays and can deliver results within approximately 60 minutes. Its ability to operate on battery power and in resource-constrained environments gives it potential applications beyond conventional laboratory infrastructure.
The company’s financial performance has also shown strong growth. Revenue from operations increased from ₹836.56 crore in FY2024 to ₹1,445.69 crore in FY2026, while PAT increased from ₹83.54 crore to ₹164.14 crore during the same period.
Another positive factor is the recurring nature of test-kit sales. The company sold approximately 1.76 crore test kits in FY2026, and test-kit revenue increased substantially over the reported period. A growing installed base of diagnostic devices can potentially support future consumable demand.
However, investors should consider the company’s dependence on government and international aid-agency procurement. The company’s offer-related disclosures indicate that a significant portion of finished-goods revenue is derived from government and international aid-agency customers. Changes in public-health programmes, procurement policies, funding or tender schedules could therefore affect business performance.
The IPO valuation is another important consideration. At the upper price band, Molbio was valued at a relatively high earnings multiple compared with several listed healthcare and diagnostics companies. Investors should therefore assess whether future revenue growth and earnings expansion can justify the valuation.
Overall, Molbio Diagnostics IPO provided exposure to an innovative molecular diagnostics company with a proprietary platform, growing revenues, international reach and increasing demand for point-of-care testing. At the same time, government procurement dependence, competition, regulatory requirements and valuation remain important risks.
Molbio Diagnostics IPO Strengths
- Proprietary Truenat point-of-care molecular diagnostics platform.
- Portable, battery-operated PCR technology designed for decentralised testing.
- Truenat platform is patented in more than 100 countries.
- Broad disease-testing portfolio covering infectious and selected non-infectious diseases.
- Growing sales of Truenat devices and diagnostic test kits.
- Strong revenue and PAT growth during FY2024 to FY2026.
- International presence across more than 55 countries.
- Exposure to growing demand for molecular and point-of-care diagnostics.
- Continued investment in research, development and manufacturing infrastructure.
- Established relationships with government and international public-health programmes.
Molbio Diagnostics IPO Risk Factors
- Significant dependence on government and international aid-agency procurement.
- Changes in public-health programmes or government spending may affect demand.
- The diagnostics industry is subject to strict regulatory and quality requirements.
- Rapid technological changes can require continued investment in R&D.
- Competition from established international and domestic diagnostic technology companies may affect market share.
- The company has exposure to customer and tender concentration risks.
- International operations are subject to regulatory, currency and geopolitical risks.
- High IPO valuation can increase downside risk if earnings growth does not meet market expectations.
- Expansion of manufacturing and R&D facilities requires effective execution and capital management.
Molbio Diagnostics IPO Promoters
The promoters of Molbio Diagnostics Limited include Sriram Natarajan, Dr. Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram and Exxora Trading LLP. The promoter and promoter-group holding was reported at approximately 46.65% before the IPO and approximately 37.69% after the IPO.
Molbio Diagnostics IPO Promoters Details
| Promoter | Designation / Role |
| Sriram Natarajan | Promoter and Executive Director & CEO |
| Dr. Chandrasekhar Bhaskaran Nair | Promoter and Executive Director & CTO |
| Sangeetha Sriram | Promoter and Executive Director & Director Operations |
| Shiva Sriram | Promoter |
| Sowmya Sriram | Promoter |
| Exxora Trading LLP | Promoter Group |
Molbio Diagnostics IPO Management Team
The company is led by an experienced management team with expertise in diagnostics, research and development, business management, technology and operations.
| Name | Designation |
| Sriram Natarajan | Executive Director & Chief Executive Officer |
| Dr. Chandrasekhar Nair | Executive Director & Chief Technology Officer |
| Sangeetha Sriram | Executive Director & Director Operations |
Molbio’s official website identifies Sriram Natarajan as Executive Director and CEO, Dr. Chandrasekhar Nair as Executive Director and CTO, and Sangeetha Sriram as Executive Director and Director Operations.
Molbio Diagnostics IPO Registrar Details
The registrar is responsible for processing IPO applications, finalising the basis of allotment, coordinating refunds and demat credit, and handling investor-related services.
| Particular | Details |
| Registrar Name | KFin Technologies Limited |
| Website | www.kfintech.com |
| IPO Allotment Status | KFin Technologies IPO Status Portal |
| Email ID | [email protected] |
| Contact Number | 040-7961 5565 |
KFin Technologies Limited was the registrar to the issue, and the reported IPO contact details included the dedicated Molbio IPO email address and KFin Technologies contact number.
Molbio Diagnostics IPO Lead Manager Details
The Book Running Lead Managers were responsible for managing the IPO process, coordinating regulatory requirements and assisting the company throughout the public issue.
| Particular | Details |
| Lead Managers | Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited and Motilal Oswal Investment Advisors Limited |
The four institutions were identified as the book-running lead managers for the Molbio Diagnostics IPO.
Molbio Diagnostics Limited Contact Details
| Particular | Details |
| Company Name | Molbio Diagnostics Limited |
| Registered Office | Plot No. L-46, Phase II D, Verna Industrial Estate, Verna, Goa – 403 722, India |
| Website | www.molbiodiagnostics.com |
| Telephone | +91-832-6724888 |
The company’s official website lists its address at Plot No. L-46, Phase II D, Verna Industrial Estate, Verna, Goa – 403 722, India, along with its telephone number.
How to Check Molbio Diagnostics IPO Allotment Status
Investors could check the IPO allotment status after the basis of allotment was finalised through the registrar’s website or stock exchange facilities.
Through KFin Technologies Limited
- Visit the official KFin Technologies IPO allotment portal.
- Select Molbio Diagnostics IPO from the available IPO list.
- Select PAN Number, Application Number or DP/Client ID.
- Enter the required details.
- Submit the information to view the allotment status.
Through BSE
- Visit the official BSE IPO status facility.
- Select Molbio Diagnostics IPO.
- Enter the PAN Number or application details.
- Complete the verification process if required.
- Submit the details to view the allotment result.
The basis of allotment was finalised on August 13, 2026, with refunds and demat credit scheduled for August 14, 2026.
Molbio Diagnostics IPO Conclusion
Molbio Diagnostics IPO provided investors with exposure to a specialised healthcare technology company focused on point-of-care molecular diagnostics. Its Truenat platform has created a differentiated position by bringing PCR-based testing closer to patients and healthcare facilities, including locations with limited laboratory infrastructure.
The company’s financial performance also showed significant growth, with revenue from operations increasing from ₹836.56 crore in FY2024 to ₹1,445.69 crore in FY2026 and PAT increasing from ₹83.54 crore to ₹164.14 crore over the same period.
The company is continuing to invest in R&D, manufacturing capacity and product development. Its international presence and growing installed base of Truenat devices provide potential opportunities for future test-kit and assay sales.
However, investors should carefully consider government and aid-agency procurement dependence, regulatory requirements, competition, technology risks and the valuation at which the shares trade after listing.
The IPO received strong demand and was subscribed approximately 70.26 times overall, while the shares listed at a substantial premium to the issue price.
A detailed assessment of Molbio Diagnostics’ financial performance, product pipeline, competitive position, customer concentration, valuation and long-term growth strategy can help investors determine whether the stock is suitable for their investment objectives.
Molbio Diagnostics IPO FAQs
What is Molbio Diagnostics IPO?
Molbio Diagnostics IPO was the Mainboard public issue of Molbio Diagnostics Limited, a point-of-care molecular diagnostics company focused on rapid and decentralised diagnostic technologies.
What was the price band of Molbio Diagnostics IPO?
The price band was ₹768 to ₹807 per equity share.
What was the issue size of Molbio Diagnostics IPO?
The total issue size was approximately ₹939.70 crore, comprising a fresh issue of ₹200 crore and an Offer for Sale of 91,66,000 equity shares.
What was the lot size of Molbio Diagnostics IPO?
The IPO lot size was 18 equity shares.
What was the minimum investment in Molbio Diagnostics IPO?
The minimum retail investment was ₹14,526 for one lot of 18 shares at the upper price band of ₹807 per share.
When did the Molbio Diagnostics IPO open and close?
The IPO opened on August 10, 2026, and closed on August 12, 2026.
When was Molbio Diagnostics IPO listed?
Molbio Diagnostics shares were listed on both BSE and NSE on August 17, 2026.
Who was the registrar for Molbio Diagnostics IPO?
KFin Technologies Limited was the registrar to the Molbio Diagnostics IPO
What does Molbio Diagnostics Limited do?
Molbio Diagnostics develops and commercialises point-of-care molecular diagnostic technologies. Its flagship Truenat platform is a portable real-time PCR system used for testing multiple infectious and non-infectious diseases.
What were the objects of the Molbio Diagnostics IPO?
The fresh issue proceeds were intended for establishing R&D and Centre of Excellence infrastructure, purchasing plant, machinery and equipment for selected manufacturing units, and general corporate purposes.
